PolyNovo Limited

The Business

PolyNovo makes NovoSorb, a fully synthetic, biodegradable polymer scaffold used to regenerate skin and soft tissue in burns and complex wounds, sold through hospitals across the US, Europe and Asia-Pacific. Unlike rivals that rely on donated or animal-derived tissue, PolyNovo's material carries no biological sourcing risk and no batch-to-batch variability, a genuine point of differentiation. The Americas, driven by non-burns wound indications and the newer MTX product, generates around three-quarters of commercial revenue. The company holds net cash and negligible debt, funded by early profitability rather than repeated capital raisings.

Recent Performance

Revenue grew 16.7% in FY26 to $143.7 million, a marked slowdown from 22% and 53% growth in the two prior years as the US hospital base matures. Underlying constant-currency growth was closer to 21%, with Australian dollar strength stripping out roughly four percentage points of reported growth. Normalised EBITDA of $13.5 million, a 9.8% margin, confirmed the business has crossed into sustained profitability, after a manufacturing fire write-off and insurance settlement complicated the reported result.

Outlook

We expect EBITDA margins to expand materially from current levels over the next several years, as revenue growth in the low double digits meets a largely fixed cost base. Employee costs, the largest expense line, should shrink relative to revenue as headcount stays broadly flat. Earnings are forecast to grow at a faster rate than revenue over that period, a compounding effect of margin expansion layered onto genuine, if decelerating, revenue growth.

Key Risks

The most significant risk is a deceleration in US growth below the mid-single digits as the existing hospital account base approaches saturation before newer products fully compensate. A second risk is a combined failure of the pending FDA premarket approval application and the Medicare outpatient reimbursement decision, either of which would cap the medium-term growth trajectory even if the existing hospital-based business remains intact. A third, entirely macro risk is a prolonged period of elevated Australian bond yields, which would keep the discount rate applied to future cash flows higher for longer, independent of anything the company does operationally.

What to Watch

The thesis-defining event is the FDA premarket approval submission expected in the second half of CY2026, which will confirm whether PolyNovo can access burns-specific reimbursement codes. The Medicare outpatient coverage decision due in CY2027 and February 2027's half-year result, which should show whether US growth and margins are tracking to plan, are the next markers to watch.

• H2 CY2026 PMA submission filing. De-risks the regulatory pathway toward burns-specific reimbursement.
• CY2027 CMS outpatient reimbursement decision. Opens a new sales channel if approved.
• Feb 2027 H1 FY27 result. Tests whether US growth and margin expansion are tracking to plan.

Company Description

PolyNovo designs, manufactures and sells NovoSorb, a synthetic biodegradable polymer used as a dermal scaffold to regenerate skin in burns, traumatic wounds, diabetic ulcers and reconstructive surgery. The core products are NovoSorb BTM (biodegradable temporising matrix) for full-thickness wounds and the newer MTX device for smaller, more complex wounds, sold through hospital and increasingly outpatient channels. The Americas is the dominant market, contributing roughly three-quarters of commercial revenue, with the balance split across Europe, the Middle East and Asia-Pacific. Unlike collagen or donor-tissue-based competitors, PolyNovo's product is fully synthetic, manufactured at a single facility in Port Melbourne, which removes biological sourcing risk but concentrates production in one site.

Where the Growth Is

The Americas, and specifically non-burns indications within it, is the growth engine. Non-burns US revenue has compounded at 52.8% annually over the past three years as surgeons adopt NovoSorb for wounds beyond its original burns approval, while the newer MTX device grew close to 90% in FY26 off a small base. Together these drive around three-quarters of commercial revenue. Any stalling as the roughly 880 penetrated US hospital accounts approach saturation is the single biggest swing factor in the forward outlook.

Competitive Position

PolyNovo's advantage rests on its synthetic polymer chemistry, protected by patents and supported by more than 500 peer-reviewed publications, an evidence base that took years to build and cannot be replicated quickly. Its 89% gross margin sits 16 to 29 percentage points above every major wound-care peer we compare it with (Integra LifeSciences at 60%, MiMedx at 85%, Organogenesis at 75%), reflecting the absence of biological sourcing costs. US market share has grown from roughly 5-8% to around 12% of the dermal matrix category as evidence accumulates and surgeons embed the product into hospital protocols, creating switching costs once adopted. Recent Medicare reimbursement reform is removing lower-evidence competitors from the category, a structural tailwind. We regard the advantage as narrow rather than wide, given it rests on a single product platform, but it is widening rather than eroding, with a competitive window we estimate at five to seven years before patent and pricing pressure intensify.

Management & Capital Discipline

Management paused the hernia repair program in FY26 to redirect resources toward the core wound-care franchise, preserving cash rather than chasing a lower-return opportunity. The company holds net cash, has taken on negligible debt, and has avoided the dilutive capital raisings common among earlier-stage med-tech peers. Chief executive Bruce Peatey has been in the role under two years, and the senior team, including the chief scientific and regulatory officers, has largely turned over within the past year, leaving a limited track record to assess. Our one reservation: management points to imminent margin expansion but has issued no quantitative guidance on timing or targets, which widens the uncertainty in any forecast built on their commentary.

Financial Position

PolyNovo holds net cash of roughly $31.8 million against equipment finance debt of only $3.6 million, giving interest coverage in excess of ten times. We estimate the business needs around $88 million of annual revenue to break even, a level it cleared in FY26 with a 36% margin of safety. Free cash flow turned positive in FY26 at $9.4 million and is expected to grow further as capital expenditure normalises following completion of the new manufacturing facility. The balance sheet can comfortably absorb a revenue downturn without needing to raise capital or draw on debt.